Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04542733
NA

The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus and Leflunomide in Treatment of BK Virus Infection in Kidney Transplantation Recipient

Sponsor: King Chulalongkorn Memorial Hospital

View on ClinicalTrials.gov

Summary

BK virus infection is one of the causes of renal allograft loss in the current era. Reduction of immunsuppression is the only intervention that prooved to be effective in treating of BK virus in kidney transplant recipient. However, there are evidences from retrospective and prospective studies showed that leflunomide and mTOR inhibitor such as everolimus or sirolimus have positive outcomes in treatment of BK virus in kidney tranplant recipient. The investigators conduct the RCT to compare the efficacy of leflunomide and mTOR inhibitor everolimus, in treatment of BK virus infected patients who do not respond to immunosuppression reduction.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2021-02-10

Completion Date

2026-07

Last Updated

2025-12-31

Healthy Volunteers

No

Interventions

DRUG

Everolimus

Everolimus will be given with tacrolimus.

DRUG

reduced dose tacrolimus and Leflunomide

Reduced dose tacrolimus will be given with leflunomide

Locations (1)

King Chulalongkorn Memorial Hospital

Bangkok, Bangkok, Thailand